Fox Run Management L.L.C. Takes Position in TG Therapeutics, Inc. $TGTX

Key Points

• Fox Run Management L.L.C. acquired a new stake in TG Therapeutics, purchasing 19,003 shares valued at approximately $749,000 in the first quarter.
• Several hedge funds, including Soleus Capital Management and Northern Trust Corp, increased their stakes in TG Therapeutics during the fourth quarter, reflecting growing institutional investment in the company.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37.00, while the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.25.

Fox Run Management L.L.C. acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 19,003 shares of the biopharmaceutical company's stock, valued at approximately $749,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TGTX. Vermillion Wealth Management Inc. purchased a new stake in shares of TG Therapeutics during the fourth quarter valued at approximately $30,000. NBC Securities Inc. lifted its position in TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares in the last quarter. Golden State Wealth Management LLC boosted its stake in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the last quarter. USA Financial Formulas bought a new stake in shares of TG Therapeutics in the 1st quarter worth $57,000. Finally, CWM LLC increased its holdings in shares of TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 290 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.64% of the company's stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, TG Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.4540 during trading hours on Thursday, reaching $28.7640. The company had a trading volume of 1,120,585 shares, compared to its average volume of 2,490,068. The firm has a market cap of $4.56 billion, a price-to-earnings ratio of 77.96 and a beta of 1.95. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The firm's 50 day moving average price is $34.40 and its 200-day moving average price is $35.73. TG Therapeutics, Inc. has a 52 week low of $21.11 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's quarterly revenue was up 92.1% on a year-over-year basis. During the same quarter last year, the business earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.